CropLife Europe fully supports the European Commission’s efforts to combat antibiotic resistance as one of the global public health threats.
ARMG were an efficient and reliable tool for the selection of GM events during the development process. In a 2004 EFSA scientific opinion, the GMO panel concluded that with regards to the safety of genes conferring resistance to kanamycin and hygromycin, including the nptII gene, “there is no rationale for inhibiting or restricting the use of genes in this category, either for field experimentation or for the purpose of placing on the market.” 2 The joint EFSA opinion of the GMO and Biohaz Panels from 2009 further complemented that “There is no experimental evidence linking antibiotic resistance marker genes of GM plants to the environmental abundance of antibiotic resistances or their genes.” 3
Button Text